Work

Evaluating the potential health and economic impact of different vaccination strategies with the adult-specific 21-valent pneumococcal conjugate vaccine in adults aged ≥ 65 years in Japan

Year: 2026
Type: article
Abstract: We estimated the health and economic impact of adult pneumococcal vaccination strategies in Japan, comparing the adult-specific PCV21 (aPCV21) to PCV20. A published Markov model simulated the epidemiology of pneumococcal disease in Japanese adults aged ≥ 65 years over a lifetime horizon using single- and multi-cohort analyses. Outcomes included cases of invasive pneumococcal disease (IPD), non-bacteremic pneumococcal pneumonia (NBPP), disease-related deaths, and direct and indirect costs (2023 Japanese yen [¥]). The base case evaluated vaccination at age 65, while scenario analyses assessed expanded age-based (≥65) vaccination, coverage rates, duration of protection, and indirect protection. Compared to PCV20, aPCV21 prevented 35% more IPD outcomes (cases and deaths) and 33% more NBPP outcomes in the base case. Combined direct and indirect disease/death-related cost savings versus no vaccination increased from ¥3,983 million with PCV20 to ¥5,299 million with aPCV21. Expanding age-based vaccination from adults aged 65 to ≥65 years, prevented an additional 12% points of IPD outcomes and 6% points of NBPP outcomes. Across all scenario analyses, aPCV21 prevented ≥ 25% more cases and costs compared to PCV20. Based on scenario analyses, the use of aPCV21 in Japanese adults provides substantial health and economic benefits compared to PCV20.
Source: Figshare
Language: English
Subfield: Epidemiology
Field: Medicine
Open Access status: green
OpenAlex ID: W7235390127
FWCI:
Cites:
Cited by:
Related to: 10